SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin

SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin

Background: Despite (neo) adjuvant chemotherapy with cisplatin, doxorubicin and methotrexate, some patients with primary osteosarcoma progress during first-line systemic treatment and have a poor prognosis. In this study, we investigated whether patients with early disease progression (EDP), are cha...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид: Evelien G. E. Hurkmans, Jan B. Koenderink, Jeroen J. M. W. van den Heuvel, Yvonne M. H. Versleijen-Jonkers, Melissa H. S. Hillebrandt-Roeffen, Johanne M. Groothuismink, Hanneke I. Vos, Winette T. A. van der Graaf, Uta Flucke, Grigor Muradjan, Hendrik W. B. Schreuder, Melanie M. Hagleitner, Han G. Brunner, Hans Gelderblom, Anne-Marie Cleton-Jansen, Henk-Jan Guchelaar, Eveline S. J. M. de Bont, Daan J. Touw, G. Jan Nijhoff, Leontien C. M. Kremer, Huib Caron, Rachael Windsor, Ana Patiño-García, Anna González-Neira, Federica Saletta, Geoff McCowage, Sumanth Nagabushan, Daniel Catchpoole, D. Maroeska W. M. te Loo, Marieke J. H. Coenen
Формат: Өгүүллэг
Хэл сонгох:English
Хэвлэсэн: Frontiers Media S.A. 2022-11-01
Цуврал:Frontiers in Pharmacology
Нөхцлүүд:
osteosarcoma
pharmacogenetics
doxorubicin
L-type amino acid transporter 2
early disease progression
Онлайн хандалт:https://www.frontiersin.org/articles/10.3389/fphar.2022.1042989/full

Интернэт

https://www.frontiersin.org/articles/10.3389/fphar.2022.1042989/full

Ижил төстэй зүйлс